Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
Posters
Scientific Publications
MaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study
Date : 19/11/2025
Download the poster
Previous Post
November 13, 2025: MaaT Pharma Launches a Capital Increase of Approximately €9 Million
Next Post
MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice
Close Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
MaaT Pharma dans les médias
MaaT Pharma in the News
Devenez membre du club
Become a member of the club